Skip to main content
. 2017 Jan 13;8(24):39746–39755. doi: 10.18632/oncotarget.14642

Figure 4. 18 cases in the pancreatic cancer group with an OS of 9.19±1.85 months, and nine cases in the pancreatic neuroendocrine tumor group with an OS of 50.10±9.21 months P < 0.05.

Figure 4

Figure 4